Shares of Retrophin Inc. (NASDAQ:RTRX) fell 2.6% on Monday . The stock traded as low as $23.59 and last traded at $23.61, with a volume of 360,350 shares traded. The stock had previously closed at $24.25.

Several research firms recently weighed in on RTRX. JMP Securities restated a “buy” rating on shares of Retrophin in a research note on Saturday, July 9th. Zacks Investment Research downgraded Retrophin from a “buy” rating to a “hold” rating in a research note on Tuesday, August 2nd. Leerink Swann restated a “buy” rating and issued a $27.00 price target on shares of Retrophin in a research note on Monday, June 27th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $28.00 price target (up previously from $25.00) on shares of Retrophin in a research note on Monday, August 8th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Retrophin presently has an average rating of “Buy” and a consensus target price of $27.60.

The stock’s 50-day moving average is $18.78 and its 200-day moving average is $16.85. The firm has a market cap of $860.24 million, a price-to-earnings ratio of 9.51 and a beta of 1.11.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.30. Retrophin had a net margin of 83.57% and a negative return on equity of 0.52%. The firm earned $33.30 million during the quarter, compared to the consensus estimate of $32.73 million. The company’s quarterly revenue was up 38.2% compared to the same quarter last year. Equities analysts anticipate that Retrophin Inc. will post $0.09 earnings per share for the current fiscal year.

In other news, EVP Alvin Shih sold 8,750 shares of Retrophin stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $16.24, for a total transaction of $142,100.00. Following the completion of the sale, the executive vice president now owns 158,334 shares of the company’s stock, valued at $2,571,344.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.41% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. First Mercantile Trust Co. increased its stake in Retrophin by 35.4% in the second quarter. First Mercantile Trust Co. now owns 5,930 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 1,550 shares in the last quarter. BlackRock Group LTD raised its position in shares of Retrophin by 54.8% in the first quarter. BlackRock Group LTD now owns 14,394 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 5,093 shares during the last quarter. BlackRock Inc. raised its position in shares of Retrophin by 479.1% in the second quarter. BlackRock Inc. now owns 13,070 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 10,813 shares during the last quarter. Alambic Investment Management L.P. raised its position in shares of Retrophin by 9.0% in the second quarter. Alambic Investment Management L.P. now owns 18,800 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 1,550 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in shares of Retrophin by 71.1% in the second quarter. UBS Asset Management Americas Inc. now owns 19,500 shares of the biopharmaceutical company’s stock valued at $347,000 after buying an additional 8,100 shares during the last quarter.

About Retrophin

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

5 Day Chart for NASDAQ:RTRX

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.